Cardiology - Reviews Open access

Anabolic hormones and heart failure with preserved ejection fraction: looking for Ariadne’s thread

Authors

Published
3 August 2021
Section
Cardiology - Reviews

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome that accounts for more than half of all heart failure patients. Identification, early diagnosis and management of patients are still complex, and no targeted treatment is available, since all tested drugs were not able to lower hard clinical outcomes. A multi-hormonal deficiency syndrome has been described in HFpEF patients suggesting that different hormones may represent new biomarkers of the disease, but their clinical utility is still debated. The natriuretic peptides are the cornerstone biomarker in heart failure, predicting cardiovascular death and heart failure hospitalization. Testosterone and DHEA-S deficiencies have been reported in HFpEF and associated with right ventricular impairment and diastolic dysfunction. IGFBP-1/IGF-1 axis correlates with echocardiographic parameters of HFpEF patients and with several prognostic biomarkers including NT-proBNP and C reactive protein. Low triiodothyronine syndrome is frequently found in HFpEF and thyroid hormones should represent a potential biomarker of risk stratification and prognosis.

References

  1. Virani SS, Alonso CA, Benjamin EJ, et al. Heart disease and stroke statistics - 2020 Update a report from the american heart association. Circulation 2020;141:139–596. DOI: https://doi.org/10.1161/CIR.0000000000000746
  2. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352-80. DOI: https://doi.org/10.1002/ejhf.2168
  3. Marra AM, Egenlauf B, Ehlken N, et al. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2015;15:19-26. DOI: https://doi.org/10.1016/j.ijcard.2015.05.105
  4. Marra AM, Arcopinto M, Bossone E, et al. Pulmonary arterial hypertension-related myopathy: an overview of current data and future perspectives. Nutr Metab Cardiovasc Dis 2015;25:131-9. DOI: https://doi.org/10.1016/j.numecd.2014.10.005
  5. Califf RM. Biomarker definitions and their applications. Exp Biol Med 2018;243:213-21. DOI: https://doi.org/10.1177/1535370217750088
  6. Salzano A, Marra AM, D'Assante R, et al. Biomarkers and imaging: complementary or subtractive? Heart Fail Clin 2019;15:321-33. DOI: https://doi.org/10.1016/j.hfc.2018.12.008
  7. De Luca M, Bosso G, Valvano A, et al. Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. Intern Emerg Med 2021;16:895-903. DOI: https://doi.org/10.1007/s11739-020-02528-4
  8. Suzuki T, Lyon A, Saggar R, et al. Editor's Choice - Biomarkers of acute cardiovascular and pulmonary diseases. Eur Heart J Acute Card 2016;5:416-33. DOI: https://doi.org/10.1177/2048872616652309
  9. Arcopinto M, Salzano A, Isgaard J, Cittadini A. Hormone replacement therapy in heart failure. Curr Opin Cardiol 2015;30:277-84. DOI: https://doi.org/10.1097/HCO.0000000000000166
  10. Bossone E, Arcopinto M, Iacoviello M. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Intern Emerg Med 2018;13:661-71. DOI: https://doi.org/10.1007/s11739-018-1844-8
  11. Senni M, D'Elia E, Emdin M, Vergaro G. Biomarkers of heart failure with preserved and reduced ejection fraction. Handb Exp Pharmaco. 2017;243:79-108. DOI: https://doi.org/10.1007/164_2016_86
  12. Tromp J, Khan MA, Klip IT, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 2017;30:6. DOI: https://doi.org/10.1161/JAHA.116.003989
  13. Salzano A, Marra AM, Ferrara F, et al. Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction. Int J Cardiol 2016; 225:1-3. DOI: https://doi.org/10.1016/j.ijcard.2016.09.085
  14. Arcopinto M, Salzano A, Bossone E, et al. Multiple hormone deficiencies in chronic heart failure. Int J Cardiol 2015;184:421-3. DOI: https://doi.org/10.1016/j.ijcard.2015.02.055
  15. Napoli R, D'Assante R, Miniero M, et al. Anabolic deficiencies in heart failure: ready for prime time? Heart Fail Clin 2020;16:11-21. DOI: https://doi.org/10.1016/j.hfc.2019.08.012
  16. Salzano A, Cittadini A, Bossone E, et al. Multiple hormone deficiency syndrome: a novel topic in chronic heart failure. Future Sci OA 2018;16:4. DOI: https://doi.org/10.4155/fsoa-2018-0041
  17. Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:413-21. DOI: https://doi.org/10.1002/ejhf.1614
  18. D'Elia E, Vaduganathan M, Gori M, et al. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail 2015;17:1231-9. DOI: https://doi.org/10.1002/ejhf.430
  19. Singh S, Pandey A, Neeland IJ. Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure. Prog Cardiovasc Dis 2020;63:649-55. DOI: https://doi.org/10.1016/j.pcad.2020.09.006
  20. Tschöpe C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005;26:2277-84. DOI: https://doi.org/10.1093/eurheartj/ehi406
  21. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. Circulation 2002;105:595–601. DOI: https://doi.org/10.1161/hc0502.103010
  22. Mogelvang R, Goetze JP, Pedersen SA, et al. Preclinical systolic and diastolic dysfunction assessed by tissue doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. J Card Fail 2009; 5:489–95. DOI: https://doi.org/10.1016/j.cardfail.2009.01.005
  23. Brouwers FP, van Gilst WH, Damman K, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Heart Fail 2014;7:723–31. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.114.001185
  24. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45. DOI: https://doi.org/10.1093/eurheartj/ehl250
  25. Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011;4:569-77. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.111.962654
  26. Volterrani M, Rosano G, Iellamo F. Testosterone and heart failure. Endocrine 2012;42:272–7. DOI: https://doi.org/10.1007/s12020-012-9725-9
  27. D'Assante R, Piccioli L, Valente P, et al. Testosterone treatment in chronic heart failure. Review of literature and future perspectives. Monaldi Arch Chest Dis 2018;88:976. DOI: https://doi.org/10.4081/monaldi.2018.976
  28. Zhao D, Guallar E, Ballantyne CM, et al. Sex hormones and incident heart failure in men and postmenopausal women: the atherosclerosis risk in communities study. J Clin Endocrinol Metab 2020;105:e3798-807. DOI: https://doi.org/10.1210/clinem/dgaa500
  29. Favuzzi AMR, Venuti A, Bruno C, et al. Hormonal deficiencies in heart failure with preserved ejection fraction: prevalence and impact on diastolic dysfunction: a pilot study. Eur Rev Med Pharmac 2020;24:352-61.
  30. Bruno C, Silvestrini A, Calarco R, et al. Anabolic hormones deficiencies in heart failure with preserved ejection fraction: prevalence and impact on antioxidants levels and myocardial dysfunction. Front Endocrinol (Lausanne) 2020;11:281. DOI: https://doi.org/10.3389/fendo.2020.00281
  31. Mancini A, Fuvuzzi AMR, Bruno C, et al. Anabolic hormone deficiencies in heart failure with reduced or preserved ejection fraction. Int J Endocrinol 2020;2020:5798146. DOI: https://doi.org/10.1155/2020/5798146
  32. D'Assante R, Napoli R, Salzano A, et al. Human heart shifts from IGF-1 production to utilization with chronic heart failure. Endocrine 2019;65:714-716. DOI: https://doi.org/10.1007/s12020-019-01993-y
  33. Arcopinto M, Salzano A, Giallauria F, et al. Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: insights from the T.O.S.CA. GHD study. PLoS One 2017;12:e0170058. DOI: https://doi.org/10.1371/journal.pone.0170058
  34. Motiwala SR, Szymonifka J, Belcher A, et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. Cardiovasc Transl Res 2014;7:250-61. DOI: https://doi.org/10.1007/s12265-013-9522-8
  35. Arcopinto M, Bobbio E, Bossone E, et al. The GH/IGF-1 axis in chronic heart failure. Endocr Metab Immune Disord Drug Targets 2013;13:76-91. DOI: https://doi.org/10.2174/1871530311313010010
  36. D'Assante R, Arcopinto M, Rengo G, et al. Myocardial expression of somatotropic axis, adrenergic, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. ESC Heart Fail 2021;8:1681-6. DOI: https://doi.org/10.1002/ehf2.13067
  37. Barroso MC, Kramer F, Greene SJ, et al. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. BMC Cardiovasc Disord 2016;16:199. DOI: https://doi.org/10.1186/s12872-016-0376-2
  38. Faxén UL, Hage C, Benson L, et al. HFpEF and HFrEF display different phenotypes as assessed by IGF-1 and IGFBP-1. J Card Fail 2017;23:293-303. DOI: https://doi.org/10.1016/j.cardfail.2016.06.008
  39. Cerbone M, Capalbo D, Wasniewska M, et al. Effects of L-thyroxine treatment on early markers of atherosclerotic disease in children with subclinical hypothyroidism. Eur J Endocrinol 2016;175:11-9. DOI: https://doi.org/10.1530/EJE-15-0833
  40. Neves JS, Vale C, von Hafe M, et al. Thyroid hormones and modulation of diastolic function: a promising target for heart failure with preserved ejection fraction. Ther Adv Endocrinol Metab 2020;11:2042018820958331. DOI: https://doi.org/10.1177/2042018820958331
  41. Vale, C, Neves, JS, von Hafe, M, et al. The role of thyroid hormones in heart failure. Cardiovasc Drugs Ther 2019;33:179-88. DOI: https://doi.org/10.1007/s10557-019-06870-4
  42. Selvaraj S, Klein I, Danzi S, et al. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol 2012;110:234-9. DOI: https://doi.org/10.1016/j.amjcard.2012.02.068
  43. Irace L, Pergola V, Di Salvo G et al. Work capacity and oxygen uptake abnormalities in hyperthyroidism. Minerva Cardioangiol 2006;54:355-62.
  44. Virtanen, VK, Saha, HH, Groundstroem, KW, et al. Thyroid hormone substitution therapy rapidly enhances left-ventricular diastolic function in hypothyroid patients. Cardiology 2001;96:59–64. DOI: https://doi.org/10.1159/000047390
  45. Sanders-van Wijk S, van Empel V, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 2015;17:1006-14. DOI: https://doi.org/10.1002/ejhf.414
  46. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-8. DOI: https://doi.org/10.3109/07853890.2010.538080
  47. Salzano A, Israr MZ, Yazaki Y, et al. Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. Eur J Prev Cardiol 2020;27:2159-62. DOI: https://doi.org/10.1177/2047487319870355
  48. Marra AM, Arcopinto M, Salzano A, et al. Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure. Int J Cardiol 2016;15:114-7. DOI: https://doi.org/10.1016/j.ijcard.2016.02.017
  49. Pergola V, Di Salvo G, Martiniello AR, et al. [TNF alpha e scompenso cardiaco].[Article in Italian]. Minerva Cardioangiol 2000;48:475-84.
  50. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-4. DOI: https://doi.org/10.1161/01.CIR.0000077913.60364.D2
  51. Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011;17:31-8. DOI: https://doi.org/10.1016/j.cardfail.2010.07.248
  52. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27. DOI: https://doi.org/10.1016/j.jacc.2009.04.078
  53. Iellamo F, Volterrani M, Caminiti G et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56:1310-6. DOI: https://doi.org/10.1016/j.jacc.2010.03.090
  54. Cittadini A, Marra AM, Arcopinto M, et al. Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. JACC Heart Fail 2013;1:325-30. DOI: https://doi.org/10.1016/j.jchf.2013.04.003
  55. Salzano A, D'Assante R, Lander M, et al. Hormonal replacement therapy in heart failure: focus on growth hormone and testosterone. Heart Fail Clin 2015;15:377-91. DOI: https://doi.org/10.1016/j.hfc.2019.02.007
  56. Salzano A, Marra AM, D'Assante R, et al. Growth hormone therapy in heart failure. Heart Fail Clin 2018;14:501-15. DOI: https://doi.org/10.1016/j.hfc.2018.05.002
  57. Salzano A, Marra AM, Arcopinto M, et al. Combined effects of growth hormone and testosterone replacement treatment in heart failure. ESC Heart Fail 2019;6:1216-1. DOI: https://doi.org/10.1002/ehf2.12520
  58. Cleland JG, Taylor J, Freemantle N, et al. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail 2012;14:487-94. DOI: https://doi.org/10.1093/eurjhf/hfs049
  59. Shah KB, Kop WJ, Christenson RH, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011;57:874-82. DOI: https://doi.org/10.1373/clinchem.2010.159277

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.